Tech Company Financing Transactions
Dauntless Pharmaceuticals Funding Round
Dauntless Pharmaceuticals secured a $12 million Series A funding round on 7/22/2015. Investors included Sofinnova Ventures.
Transaction Overview
Company Name
Announced On
7/22/2015
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Series A
Investors
Sofinnova Ventures (David Kabakoff)
Proceeds Purpose
The financing will fund the development of DP1038, a preclinical-stage drug for the potential treatment of endocrine cancers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9920 Pacific Heights Blvd. 150
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
We provide a creative way to advance programs that may not be funded within existing pharmaceutical research budgets. We license the asset from pharmaceutical and biotechnology companies, finance the development of the program, and provide a mechanism for the licensor to regain rights on clinical success.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joel Martin
VP - Bus. Development
Olivier Laurent
VP - Operations
Mark Daniels
VP - Regulatory Affairs
Michelle Mazzoni
Browse more venture capital transactions:
Prev: 7/22/2015: Rex Computing venture capital transaction
Next: 7/22/2015: Homer Logistics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs